Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Advanced or Metastatic Renal Cell Carcinoma, Renal Cancer
Both
Advanced or Metastatic Renal Cell Carcinoma, Renal Cancer
Trial Information
Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With Sutent
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated
for 1st or 2nd line anticancer therapy
Inclusion Criteria:
- Consecutive patients with advanced or metastatic renal cell carcinoma, that are
indicated for 1st or 2nd line anticancer therapy
Exclusion Criteria:
- Hypersensitivity to sunitinib malate or to any of the excipients
- Any other contraindication to the use of sunitinib malate (based on decision of the
treating physician).
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib
Outcome Time Frame:
36 months
Safety Issue:
No
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Slovakia: Ethics Commitee of the Bratislava Selgf-Governing Region
Study ID:
A6181185
NCT ID:
NCT00873210
Start Date:
May 2009
Completion Date:
November 2011
Related Keywords:
- Advanced or Metastatic Renal Cell Carcinoma
- Renal Cancer
- renal cell carcinoma
- sunitinib malate
- Carcinoma
- Carcinoma, Renal Cell
- Kidney Neoplasms
Name | Location |
|---|
